Shanghai Apeloa Pharmaceutical Research Institute

Shanghai, China

Shanghai Apeloa Pharmaceutical Research Institute

Shanghai, China
Time filter
Source Type

Lin Y.,Shanghai JiaoTong University | Lin Y.,Meisei University | Kong H.,Shanghai JiaoTong University | Wu D.,Shanghai JiaoTong University | And 3 more authors.
World Journal of Microbiology and Biotechnology | Year: 2010

This work concerned the study of ammonia oxidation by a heterotrophic bacterium, Bacillus sp. LY, isolated from a membrane bioreactor (MBR) treating a synthetic domestic wastewater with 15-l working volume. During the batch test 74.8% of ammonium and 61.0% of CODCr were removed, and the maximum nitrification rate was 173.6 mgN/(g dry weight day). The ammonia oxidation ability was inhibited by high organic substrate concentrations and was highest in the poorest medium. The isolate oxidized ammonia to NH2OH, and the presence of ammonia monooxygenase (AMO) in Bacillus sp. LY was further confirmed by a specific 491-bp fragment of the amoA gene, but the results of PCR amplification suggest that amoB may not be a member of the amo operon in this isolate. Moreover, from the nitrogen balance, the percentage of nitrogen lost in a batch test was estimated to be 61.9%, which was presumed to have been removed via aerobic denitrification. © 2010 Springer Science+Business Media B.V.

Zhang L.,Shanghai JiaoTong University | Shen X.,Shanghai JiaoTong University | Lu Q.,Shanghai JiaoTong University | Zhou Q.,Shanghai Apeloa Pharmaceutical Research Institute | And 5 more authors.
Graefe's Archive for Clinical and Experimental Ophthalmology | Year: 2012

Background Endogenous angiogenesis inhibitors act as natural negative feedback in the focal area during the neovascularization process, and have less interference on physiological angiogenesis, and thus fewer negative sideeffects. These inhibitors are potential candidates to combine with or substitutes for current popular anti-angiogenesis treatments to have synergistic effect. In this study, the effects of recombinant endothelial growth inhibitor protein (rhEDI-8t), a novel endogenous protein originated from collagen VIII, was investigated on ocular neovascularization (NV). Endostatin, a well-identified endogenous angiogenesis inhibitor, was compared in parallel and served as a positive control. Methods The inhibitory effect of rhEDI-8t on vascular endothelial cells was evaluated by a human umbilical vascular endothelial cells (HUVEC) proliferation test and a bovine aortic endothelial cells (BAEC) migration experiment. The effect of rhEDI-8t on ocular NV was further investigated in mice with choroidal neovascularization (choroidal NV) induced by laser, ischemic retinopathy and transgenic mice with expression of VEGF in photoreceptors (rho/VEGF) respectively. Results RhEDI-8t inhibited the growth of HUVECs and migration of BAECs stimulated by basic fibroblast growth factor (bFGF). Mice intravitreally treated with rhEDI-8t showed a significant reduction of choroidal NV, retinal NV and subretinal NV. Conclusion Endogenous angiogenesis inhibitor rhEDI-8t showed a potent anti-angiogenesis effect in both in vitro and in vivo experiments. It contributed to the suppression of ocular NV. The study suggested that rhEDI-8t could be a subsidiary potent therapeutic medicine in addition to anti- VEGF therapy in future clinical anti-angiogenesis treatment. © 2011 Springer-Verlag.

Lu Q.,Shanghai JiaoTong University | Zhang L.,Johns Hopkins University | Shen X.,Shanghai JiaoTong University | Zhu Y.,Shanghai JiaoTong University | And 6 more authors.
Experimental Eye Research | Year: 2012

Neovascularization is the critical pathological process and the leading cause of blindness in a variety of clinical conditions. This angiogenesis process is still uncertain. Human hepatocyte growth factor 1 (HGFK1) is derived from the mature form of hepatocyte growth factor, which contains four kringle domains in its α-chain. This study aimed to investigate the antiangiogenic activity of HGFK1 using in vitro and in vivo assays. HGFK1 was added into the DMEM to test the proliferation and migration of human umbilical vascular endothelial cells (HUVEC), and it was intravitreously injected in laser photocoagulation-induced choroidal neovascularization (NV) model, oxygen-induced retinopathy model and rho/VEGF transgenic mice to test its antiangiogenic effect. The results showed that HGFK1 effectively inhibited VEGF-stimulated HUVEC proliferation and migration, and also had anti-NV activity in choroidal NV and retinal NV. It is suggested that HGFK1 has antiangiogenic activity in vitro and in vivo. It may lead to new potential drug discoveries and the development in addition to anti-VEGF therapy in the future clinical anti-angiogenesis treatment. © 2012 Elsevier Ltd.

Zhou Q.,Shanghai Apeloa Pharmaceutical Research Institute | Du P.,Shanghai Apeloa Pharmaceutical Research Institute | Qian Y.,Shanghai Apeloa Pharmaceutical Research Institute | Zhang Q.,Shanghai Apeloa Pharmaceutical Research Institute | And 4 more authors.
Shengwu Gongcheng Xuebao/Chinese Journal of Biotechnology | Year: 2010

On the basis of the origin comparison of known endothelial genesis inhibitors, a 417-bp cDNA fragment was amplified from umbilical cord by RT-PCR and cloned into the expression vector pPIC9, followed by transformation into Pichia pastoris GS115. The resulted yeast was induced with methanol to express recombinant protein. The resulted protein was purified from culture broth and designated as EDI-8t. The in vitro study showed that EDI-8t, originated from collagen VIII, could specifically inhibit the growth and migration of bovine aortic endothelial cells (BAEC) stimulated by basic fibroblast growth factor (bFGF). The protein also exhibited the activity to cause cell apoptosis. In vivo EDI-8t showed the identical activity comparing with endostatin to inhibit the growth of liver tumor transplanted into nude mice. Interestingly, EDI-8t showed higher activity than endostatin to inhibit tumor growth in metastatic model of melanoma mice.

Loading Shanghai Apeloa Pharmaceutical Research Institute collaborators
Loading Shanghai Apeloa Pharmaceutical Research Institute collaborators